Tolerability Study News Today

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXI...

The OASIS trial is a first-in-class clinical trial combining a CD19-expressing oncolytic virus, which flags solid tumours for attack by CD19-targe...

UZEDY significantly reduced the risk of relapse by up to 80% and prolonged the time to impending relapse by up to 5.0 times while having a similar safety profile to other formulations of... | May 20, 2023

ALPHARETTA, Ga., April 27, 2023 -- Clearside Biomedical, Inc. , a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ,... | April 27, 2023

Imugene Ltd (ASX:IMU, OTC:IUGNF) welcomes the news that the first patients have been dosed in its Phase 1 MAST (metastatic advanced solid tumours) study...

Imugene Ltd (ASX:IMU, OTC:IUGNF) has received Human Research Ethics Committee (HREC) approval to kick off an Australian Phase 1 clinical trial of its...

ND0612, a continuous 24 hours/day subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the...

Imugene has now crossed ethics approval off is list, and the way is now clear for clinical trials to begin in Australia.

ND0612, a continuous 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.